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 Discordant Regulation of microRNA Between 
Multiple Experimental Models and Human 
Pulmonary Hypertension 
 Kenny  Schlosser ,  PhD ;  Mohamad  Taha ,  BSc ;  Yupu  Deng ,  MD ;  Baohua  Jiang ,  MD ,  PhD ; and  Duncan J.  Stewart ,  MD 
 BACKGROUND:  Th e dysregulation of microRNA (miRNA) is known to contribute to the patho-
biology of pulmonary arterial hypertension (PAH). However, the relationships between 
changes in tissue and circulating miRNA levels associated with diff erent animal models and 
human pulmonary hypertension (PH) have not been defi ned. 
 METHODS:  A set of miRNAs that have been causally implicated in PH, including miR-17, -21, 
-130b, -145, -204, -424, and -503, were measured by reverse transcription-quantitative poly-
merase chain reaction in the plasma, lung, and right ventricle of three of the most common 
rodent models of PH: the rat monocrotaline and SU5416 plus chronic hypoxia (SuHx) models 
and the mouse chronic hypoxia model. Plasma miRNA levels were also evaluated in a cohort 
of patients with PAH and healthy subjects. 
 RESULTS:  Several miRNA showed PH model-dependent perturbations in plasma and tissue 
levels; however, none of these were conserved across all three experimental models. Principle 
component analysis of miR expression changes in plasma revealed distinct clustering between 
rodent models, and SuHx-triggered PH showed the greatest similarity to human PAH. Changes 
in the plasma levels of several miRNA also correlated with changes in tissue expression. In 
particular, miR-424 was concordantly increased (1.3- to 1.5-fold,  P  , .05) in the plasma, lung, 
and right ventricle of hypoxic mice and in the plasma of patients with PAH. 
 CONCLUSIONS:  miRNAs with established etiologic roles in PH showed context-dependent 
changes in tissue and circulating levels, which were not consistent across rodent models and 
human PAH. Th is suggests diff erent miRNA-dependent mechanisms may contribute to exper-
imental and clinical PH, complicating potential diagnostic and therapeutic applications ame-
nable to these miRNAs.  CHEST 2015; 148(2): 481 - 490 
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 microRNAs (miRNAs) are short (approximately 22 nt) 
non-protein-coding RNA molecules that regulate gene 
expression at the posttranscriptional level by directing 
the translational inhibition or degradation of cognate 
messenger RNAs. To date,  . 2,500 mature human 
miRNAs have been reported, 1 which are predicted to 
control the majority of protein-coding genes. 2 The 
dysregulated cellular expression of miRNAs has 
been implicated in the etiology of many diseases, 3 
including, more recently, pulmonary arterial hyperten-
sion (PAH). 4 Th is progressive disease is characterized by 
changes in the structure and function of the pulmonary 
vasculature, which precipitates right-sided heart failure. 5 
 A number of miRNAs, including miR-17, miR-21, 
miR-130, miR-145, miR-204, miR-424, and miR-503, 
have been demonstrated to be causally involved in the 
development of pulmonary hypertension (PH). 6-12 Th e 
aberrant expression of these miRNAs in lung vascular 
cells is known to contribute to the dysregulation in pro-
liferation, apoptosis, and infl ammation that underlie PH. 4 
Moreover, these miRNAs have been proposed as poten-
tial targets for therapeutic intervention. 6-12 Indeed, strat-
egies designed to reverse pathologic changes in lung 
miRNA expression have previously shown promise in 
attenuating hemodynamic and/or vascular remodeling 
abnormalities in preclinical animal models of PH. 6-12 
Although experimental PH induced by the combination 
of SU5416 and chronic hypoxia (SuHx) in rats has been 
suggested to most closely model human PAH, 13 miRNAs 
have mainly been assessed in the monocrotaline (MCT) 
or chronic hypoxia (Hx) models. Although these models 
can reproduce important features of human PAH, 
they generally lack the severe pulmonary arteriopathy 
observed in patients with PAH. Whether the regulation 
of miRNA is conserved between these diff erent experi-
mental models has not yet been established, but this 
may provide important clues to help diff erentiate 
model-specific alterations from changes that may 
relate to more central mechanisms in the pathobiology 
of PH. 
 We analyzed the expression of these seven miRNAs 
across three of the most commonly used rodent models 
of PH, including MCT rats, SuHx rats, and Hx mice. 
Th e expression patterns were assessed in the lung as well 
as two other biologic sources that have largely been 
overlooked in previous studies, the right ventricle and 
plasma. Of note, plasma has become increasingly recog-
nized as a key source of extracellular miRNAs, which 
have the potential to serve as practical noninvasive bio-
markers of disease. 14 Th is application would be particu-
larly useful in PAH given the diffi  culty associated with 
the early diagnosis of this condition. 15 Moreover, the 
convenience of plasma collection circumvents some of 
the inherent challenges of obtaining clinically relevant 
biologic specimens from patients, which can facilitate 
broader studies on the pathobiology of PAH and pro-
vide direct insight into the human disease. We, there-
fore, also examined the expression pattern of these 
seven miRNAs in a cohort of patients with PAH and 
healthy subjects. 
 We now report a surprising lack of concordance in the 
pattern of miRNA expression between diff erent rodent 
models of PH and between experimental and human 
PH. Th ese fi ndings have important implications for the 
potential usefulness of miRNAs identifi ed in experi-
mental PH for application as biomarkers and thera-
peutic targets in human PAH. In addition, our results 
provide new molecular evidence supporting SuHx-
induced PH as a more relevant model of human PAH. 
 Results 
 Basal miRNA Expression Patterns Largely 
Conserved Between Species 
 Plasma levels of individual miRNA varied by nearly 
three orders of magnitude and generally followed 
the rank order: miR-204  , miR-503  , miR-130b  , 
miR-424  , miR-17  , miR-145  , miR-21 ( Fig 1A ) . Inter-
estingly, this pattern was largely conserved across humans, 
rats, and mice under physiologic conditions, with the 
exception of miR-145, which ranked below miR-424 in 
human plasma ( Fig 1A ). miRNA expression patterns in 
the lung and right ventricle were also comparable between 
rats and mice ( Fig 1A ), and only modest diff erences in 
 Material and Methods 
 Peripheral blood samples from patients with PAH and healthy subjects 
were obtained with informed consent, under a protocol approved by 
the Ottawa Hospital Research Ethics Board (#2011470-01H), as pre-
viously described. 16 All animal procedures were approved by the 
University of Ottawa’s Animal Care Ethics Committee and complied 
with the principles and guidelines of the Canadian Council on Animal 
Care. A detailed description of the inclusion/exclusion criteria for 
human subjects, animal models, plasma isolation, total RNA extraction, 
RNA quality control assessment, reverse transcription-quantitative 
polymerase chain reaction, reference control characterization (e-Fig 1), 
and statistics is provided in  e-Appendix 1 . 
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 Figure 1 – A, B, Relative levels of 
miRNAs in plasma, lung, and RV 
across humans, rats, and mice. A, 
Plasma miRNA levels were measured 
by reverse transcription-quantitative 
polymerase chain reaction (RT-qPCR) 
and normalized to internal reference 
controls (miR-142-3p and miR-320a 
for humans and miR-24-3p for rats 
and mice). Data were scaled to the 
lowest miRNA in each group (mean 
level from approximately two- to 
21-fold above assay detection limit), 
which was set to one. miRNA levels in 
the lung and RV were normalized 
to RNU6-2 and scaled to the lowest 
miRNA in each group (mean level at 
least 50-fold above the assay detection 
limit). Data are presented as mean   
range for n  5 13 healthy human 
subjects, n  5 10 control CDF rats, 
n  5 13 control S-D rats, and n  5 11 
control C57Bl6J mice. B, Correlation 
between relative miRNA levels in 
plasma and either lung or RV. Pearson 
correlation coeffi  cients ( r ) are shown 
for log transformed data (* P  , .05, 
** P  , .01). Each symbol represents 
the mean level of one of the seven 
miRNAs under investigation. CDF  5 
Fischer; miRNA  5 microRNA; 
RV  5 right ventricle; S-D  5 Sprague-
Dawley . 
the rank order of miRNA expression were evident 
between plasma and tissues. Overall, a strong positive 
correlation was observed between plasma miRNA levels 
and their corresponding expression levels within the 
lung (Pearson  r  5 0.89-0.90,  P  , .01 for rats; and Pearson 
 r  5 0.95,  P  , .01 for mice) and right ventricle (Pearson 
 r  5 0.87-0.88,  P  , .05 for rats; and Pearson  r  5 0.80, 
 P  , .05 for mice) ( Fig 1B ). Th is correlation was consis-
tently observed across rats (both Fischer and Sprague-
Dawley strains) and mice. 
 Predominant miRNA Downregulation in MCT Rats 
 Rats received a single intraperitoneal injection of MCT 
(or vehicle control), and right ventricular systolic pres-
sure (RVSP) and right ventricular hypertrophy (right 
ventricle to left ventricle plus septum [RV/(LV  1 S)]
mass ratio) were significantly increased 3 weeks 
post MCT injection ( Figs 2A, 2B ) . Th e plasma levels of 
both miR-322 (the rat homolog of human miR-424) 
and miR-503 were signifi cantly decreased in MCT rats 
relative to control rats (1.3-fold down,  P  , .01 and 
1.8-fold down,  P  , .001, respectively) ( Fig 2C ), which 
mimicked a signifi cant decline in lung tissue expres-
sion (3.7-fold down,  P  , .0001 and 5.6-fold down, 
 P  , .0001, respectively). miR-204 was decreased in 
lung tissue in MCT rats (1.9-fold down,  P  , .01) and 
showed a trend ( P  5 .097) toward lower levels in the 
plasma. miR-145 was also decreased in the lung 
(2.0-fold,  P  , .0001) and right ventricle (1.3-fold,  P  , .05) 
of MCT rats, whereas no change in plasma level was 
detected. miR-130b was decreased in the lung of 
MCT rats (1.7-fold down,  P  , .01) but showed a trend 
( P  5 .07) toward higher levels in plasma. Only miR-21 
was increased, showing trends toward higher levels in 
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plasma ( P  5 .07) and a signifi cant increase in lung 
tissue expression (3.2-fold up,  P  , .0001). Th e plasma, 
lung, and right ventricle levels of miR-17 were not 
altered in MCT rats. 
 Modest miRNA Changes in SU5416/Hx Rats 
 Rats received a single subcutaneous injection of the 
vascular endothelial growth factor receptor-2 inhibitor, 
SU5416 (or vehicle control) and were exposed to hyp-
oxic conditions (10% oxygen) for a period of 3 weeks, 
followed by 5 weeks of normoxic conditions ( Fig 3A ) . 
Plasma, lung, and right ventricle miRNA levels were 
measured aft er 8 weeks, at which time there was a 
signifi cant increase in RVSP and RV/(LV  1 S) mass 
ratio ( Fig 3B ). Surprisingly, despite the severity of the 
PH phenotype, levels of these specifi c miRNAs were not 
signifi cantly altered in plasma or lung between SuHx 
and control groups ( Fig 3C ), and only miR-145 showed 
a trend toward increased levels in the lung. Th e only 
signifi cant changes in tissue miR expression were seen 
in the right ventricle of SuHx rats, with a twofold 
increase in miR-21 ( P  , .01) and twofold decrease in 
miR-204 ( P  , .05) ( Fig 3C ). 
 miRNA Upregulation in Hx Mice 
 Mice were exposed to Hx for 3 weeks ( Fig 4A ), aft er 
which time there were modest increases in RVSP and 
RV/(LV  1 S) mass ratio ( Fig 4B ). In contrast to the 
MCT model, a general pattern of upregulation was 
observed among the miRNAs that were altered in 
hypoxic mice. One miRNA in particular, miR-322 (the 
mouse/rat homolog of human miR-424), was shown to 
be signifi cantly and concordantly higher in the plasma 
(1.3-fold,  P  , .05), lung (1.4-fold,  P  , .001), and right 
ventricle (1.4-fold,  P  , .05) of hypoxic mice vs control 
mice ( Fig 4C ). Th e expression of miR-503 was also sig-
nifi cantly higher in the lung and right ventricle of Hx 
mice, but plasma levels were not signifi cantly altered. 
Th e plasma levels of miR-17 were signifi cantly elevated 
in Hx mice (1.4-fold,  P  , .01), whereas no changes in 
expression were observed in the lung or right ventricle. A 
trend ( P  , .1) toward higher plasma levels of miR-204 was 
 Figure 2 – A-C, MCT rat model of 
pulmonary hypertension. A, Experi-
mental outline. Male CDF rats were 
given a single intraperitoneal injec-
tion of MCT or vehicle control 
(n  5 10-11/group). Plasma, lung, 
and RV tissue were collected 3 wk later. 
B, RVSP and RV/(LV  1 S) mass 
ratio. Data are presented as boxplots 
with whiskers showing minimum-
maximum range. C, Relative miRNA 
levels were measured by RT-qPCR. 
Plasma miRNA levels were normalized 
to an internal reference control (miR-
24-3p), and expressed relative to the 
control group. miRNA levels in the 
lung and RV were normalized to 
RNU6-2 and expressed relative to the 
control group. Data are presented as 
mean   SEM # P  , .1, * P  , .05, 
** P  , .01, *** P  , .001, **** P  , .0001 
vs control group. miR-322 is the rat 
homolog of human miR-424. Con  5 
control; IP  5 intraperitoneal; LV  5 left  
ventricle; MCT  5 monocrotaline; 
RV/(LV  1  S)  5 right ventricle to left  
ventricle plus septum; RVSP  5 right 
ventricular systolic pressure. See 
 Figure 1 legend for expansion of 
other abbreviations. 
 journal.publications.chestnet.org  485 
evident in Hx mice, but no signifi cant diff erence in lung 
or right ventricle tissue was detected. Both miR-21 and 
miR-145 were increased in the lungs of Hx mice (1.6- and 
1.4-fold, respectively;  P  , .001), with no change in plasma 
or right ventricle levels. No signifi cant changes in the plasma, 
lung, or right ventricle levels of miR-130b were observed. 
 Principle Component Analysis Underscores 
Diﬀ erences Between Models 
 To gain further molecular insight into the relative simi-
larity or dissimilarity between experimental models, 
principle component analysis (PCA) was conducted on 
miRNA expression changes in plasma, lung, and right 
ventricle. Th e 21-dimensional miRNA expression space 
(defi ned by changes in the seven target miRNAs across 
three diff erent biologic sources) was linearly transformed 
and mapped into just two dimensions (ie, principle 
components) to facilitate visualization and comparison 
of the variability among individual rodents within and 
between each PH model ( Fig 5A ) . Th e distance between 
any pair of individuals in the PCA plot is related to the 
degree of similarity between the two individuals in high-
dimensional space. Th e animals in each experimental 
model formed distinct clusters, with some overlap 
observed among rodents exposed to hypoxia alone or 
in combination with SU5416. Animals in the MCT and 
hypoxia models showed the greatest separation in prin-
ciple component space, which contrasted with their 
relative closer proximity in a biplot comparison of their 
phenotypic abnormalities in RVSP and RV/(LV  1 S) 
mass ratio ( Fig 5B ). 
 To gain insight into whether the discordance in miRNA 
regulation between models was also refl ected in the 
regulation of downstream messenger RNA targets, we 
examined two specifi c messenger RNAs (mRNAs) 
( Fgf2 and  Rhob ) that are known to be direct targets of 
miR-424/503 and miR-21, respectively 7,8 ( e-Fig 2 ).  Fgf2 
transcript levels were signifi cantly elevated in lung 
tissue from both rat models of PH (1.4-fold in SuHx and 
1.5-fold in MCT,  P  , .05), but no signifi cant change was 
observed in the lungs of hypoxic mice vs control mice. 
Th e mRNA level of  Rhob was downregulated in SuHx 
rat lungs (1.2-fold,  P  , .05), whereas no signifi cant 
change was observed in the lungs of MCT rats or Hx 
mice. Of note, the increased  Fgf2 level in the lungs of 
 Figure 3 – A-C,  SuHx rat model of 
pulmonary hypertension. A, Experi-
mental outline. At d 0, male S-D rats 
were given a single SC injection 
of SU5416 or vehicle control 
(n  5 9-13/group). Rats were housed 
under hypoxic conditions for the 
fi rst 3 wk and then held in normoxic 
conditions for another 5 wk until 
study end point. Plasma, lung, and 
RV tissue were collected at end point 
(8 wk aft er SU5416 injection). 
B, RVSP and RV/(LV  1 S) mass ratio. 
Data are presented as boxplots 
with whiskers showing minimum-
maximum range. C, Relative miRNA 
levels were measured by RT-qPCR. 
Plasma miRNA levels were normal-
ized to an internal reference control 
(miR-24-3p) and expressed relative 
to the control group. miRNA levels in 
the lung and RV were normalized to 
RNU6-2 and expressed relative to 
the control group. Data are presented 
as mean   SEM. # P  , .1, * P  , .05, 
** P  , .01 vs control group. miR-322 
is the rat homolog of human miR-424. 
O 2   5 oxygen; SC  5 subcutaneous; 
 SuHx  5  SU5416 plus chronic hypoxia . 
See  Figure 1 and 2 legends for 
expansion of other abbreviations. 
 486  Original Research  [   1 4 8  #  2   C H E S T   AU G U S T   2 0 1 5   ] 
MCT rats was consistent with the observed decrease in 
miR-322/503 in this model. However, this expected 
inverse relationship between mRNA target and miRNA 
was not directly observed in other models or between 
 Rhob and miR-21 ( e-Fig 2 ). 
 PCA Exposes Relative Similarity Between 
Human and SuHx-Triggered PH 
 To gain insight into which experimental trigger of PH 
most closely models the molecular changes associated 
with human PAH, target miRNAs were also measured 
in plasma from 14 patients with PAH (58   10 years, 
57% women) and 13 healthy control subjects (45   13 years, 
69% women) ( Fig 6A ) . Th e PAH patient cohort was 
composed of both idiopathic (43%) and associated 
forms (57%) of the disease, of which the majority (79%) 
were on PH-specifi c therapy at the time of blood sam-
pling. Detailed clinical characteristics of this patient 
cohort have been described previously 16 ( e-Table 1 ). Th e 
plasma level of miR-17 was decreased in patients with 
PAH (1.4-fold,  P  , .05), and miR-145 also showed a 
trend toward lower levels (1.3-fold,  P  , .1). An increase 
in miR-424 was observed in patients with PAH (1.5-fold, 
 P  , .05), whereas levels of miR-21, -130b, -204, and -503 
were not signifi cantly diff erent between patients with 
PAH and healthy control subjects. However, it should 
be noted that these miRs were originally linked to PH by 
interrogation of other biologic samples, including cell 
and lung tissue specimens, 8,9 or by comprehensive in 
silico network analyses. 7 PCA of the plasma changes in 
these seven miRNAs exposed a relative similarity in the 
underlying miR regulation between patients with PAH 
and rodents with SuHx-triggered PH ( Fig 6B ). In prin-
ciple component space, SuHx rats showed the closest 
overlap with patients with PAH and also exhibited a 
similar degree of heterogeneity in the miRNA response 
among individuals. In comparison, rodents from the 
MCT and Hx models were distributed in tighter clusters 
within the PCA plot. 
 Potential Diagnostic Biomarkers of PAH 
 For miRNAs that were altered in the plasma of patients 
with PAH, receiver operating characteristic (ROC) 
curve analysis was conducted to gauge their potential 
 Figure 4 – A-C, Hx mouse model of 
pulmonary hypertension. A, Experi-
mental outline. Male C57Bl6J mice 
were housed under hypoxic or control 
normoxic conditions (n  5 10-11/group) 
for 3 wk aft er which time plasma, 
lung, and RV tissue were collected. 
B, RVSP and RV/(LV  1 S) mass ratio. 
Data are presented as boxplots with 
whiskers showing minimum-maximum 
range. C, Relative miRNA levels were 
measured by RT-qPCR. Plasma 
miRNA levels were normalized to 
an internal reference control (miR-
24-3p) and expressed relative to the 
control group. miRNA levels in the 
lung and RV were normalized to 
RNU6-2 and expressed relative to the 
control group. Data are presented as 
mean   SEM # P  , .1, * P  , .05, 
** P  , .01, *** P  , .001 vs control group. 
miR-322 is the mouse homolog of 
human miR-424. Hx  5 chronic 
hypoxia. See  Figure 1-3 legends for 
expansion of other abbreviations. 
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diagnostic usefulness. miR-424 and miR-17 both exhib-
ited signifi cant areas under their corresponding ROC 
curves (area under the ROC curve of 0.76 and 0.73, 
respectively;  P  , .05) ( Fig 6C ) and exhibited the capacity 
for high sensitivity (0.93 for both miR-424 and miR-17; 
95% CI, 0.66-1.00) and moderate specifi city (0.69; 
95% CI, 0.39-0.91 and 0.62; 95% CI, 0.32-0.86, respec-
tively) in discriminating between patients with PAH and 
healthy participants. However, no signifi cant correlation 
was observed between plasma miRNA level and various 
physiologic indexes of disease severity in this small 
cohort, including mean pulmonary artery pressure, pul-
monary vascular resistance index, and the 6-min walk 
distance test (data not shown). 
 Discussion 
 Th is study provides one of the most extensive assessments 
of PH-induced changes in miRNA expression reported 
to date. Th e expression patterns of seven miRNAs were 
analyzed in the plasma, lung, and right ventricle of three 
of the most commonly used rodent models of PH and in 
plasma from patients with PAH. We focused specifi cally 
on a set of miRNAs that have previously been impli-
cated causally in PAH, based on supporting evidence 
that included loss- and/or gain-of-function experiments 
in cells and/or specifi c animal models. 6-10,12 In contrast 
to previous studies that have investigated the specifi c 
molecular mechanisms of individual miRNAs, the cur-
rent study now helps to answer broader questions about 
the nature of their regulation across diff erent biologic 
sources, species, and experimental vs clinical forms of 
PH. Th is may provide new perspectives on the molec-
ular pathobiology of PH and important insight on the 
translational potential of animal studies and the related 
merits of therapeutic strategies aimed at reversing path-
ologic changes in miRNA expression. 
 We found that each of the target miRNAs was detect-
able in the plasma of mice, rats, and humans. Moreover, 
the relative rank order of plasma miR levels was highly 
conserved across species, suggesting that similar mecha-
nisms may control the basal release and clearance of 
these miRNAs from circulation across these species. 
Of note, the plasma miR levels in three separate animal 
models consistently showed strong positive correlations 
with miRNA levels in the lung. Although not defi nitive 
evidence, this correlation does suggest that circulating 
miR levels may be driven at least in part by the magni-
tude of lung expression, consistent with the fact that the 
lung represents the largest vascular bed with the greatest 
opportunity to release or clear miRNAs across the pul-
monary circulation. 
 Interestingly, none of the PH-associated changes in 
plasma miRNA levels were common between two or 
more of the experimental models ( Table 1 ) . However, 
these discordant patterns were not limited to circulating 
miRNAs, as both lung and RV miRNA expression 
showed distinct model-specific patterns of change. 
The known mRNA targets of two miRNAs were also 
examined in the lungs of each model. Although 
  
 Figure 5 – A, B, PCA mapping of miRNA expression changes in three rodent models of pulmonary hypertension. A, Hx (  ), SuHx ( L ), and MCT (  ) 
denote individual animals from each experimental model. For each animal, the change in seven target miRNAs measured across three diff erent biologic 
sources (plasma, lung, and RV) were mapped to a position in two-dimensional space (ie, PCs) for easy visualization. Th e distance between any pair of 
animals in the PCA plot is related to the degree of similarity between the two observations in higher dimensional space. A total of 47.1% of the entire 
information content of the 21-dimensional miRNA expression space is captured in the two-dimensional PCA plot, with 32.4% and 14.7% of the variability 
in data explained by PC1 and PC2, respectively. Ellipses denote 1.5 SDs, and line vectors connect to the centroid. B, Biplot showing distribution of individual 
animals from various pulmonary hypertension models according to their RV/(LV  1 S) and RVSP. Data are presented as fold change to mean baseline 
level in control animals. PC  5 principle component; PCA  5 principle component analysis. See  Figure 1-4 legends for expansion of other abbreviations. 
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other miRNA targets. Th is suggests that in these cases 
miRNA may not be the sole or even the most important 
mechanism of regulation for these targets. In previous 
studies, miRNA expression changes associated with 
experimental PH have commonly been evaluated in 
lung tissue, and our assessment of miRNA expression 
changes were generally quite comparable to previous 
reports 6-11,17 ( e-Table 2 ); however, there were a few 
exceptions that we speculate could be attributed to dif-
ferences in the experimental time course and severity of 
PH or possibly other study-specifi c factors (eg, animal 
strain) ( e-Table 2 ). 
 Of note, within each model system we observed similar 
changes in the PH-associated miRNA levels in plasma 
and tissues. A general pattern of downregulation was 
observed among miRNAs that were altered in the MCT 
model (ie, fi ve of six altered miRs), which contrasted 
with a general pattern of upregulation among the 
miRNAs that were altered under hypoxic conditions. 
Th e divergence in miR regulation between these models 
was further supported by PCA, in which rodents with 
MCT-induced PH clearly formed a distinct cluster separate 
from rodents with hypoxia-induced PH. It is intriguing 
that the same miRNAs are diff erentially regulated in 
these two models of PH. Certainly, Hx and MCT pro-
duce distinct PH phenotypes that likely involve diff erent 
molecular mechanisms; however, it remains possible 
that some changes may refl ect off -target eff ects of the 
specific stimuli used to induce PH. In contrast, we 
found only modest changes in the mean miRNA levels 
in the SuHx model of PH, despite far greater abnormal-
ities in hemodynamics and RV remodeling. Neverthe-
less, the distribution of individual animals/patients 
revealed in the PCA plot of changes in plasma miRNA 
suggests this model may more closely resemble human 
PAH than the MCT and hypoxia models. Th is is consis-
tent with the similarities in cellular and histologic 
abnormalities (ie, plexiform lesions) and progressive 
irreversible phenotype that have previously supported 
the SuHx model as most relevant to the human disease. 18 
 miR-424 was the only miRNA to show concordant 
changes in the plasma of humans and at least one exper-
imental model of PH, Hx. In hypoxic mice, elevated 
plasma levels of miR-322 (the mouse analog of human 
miR-424) also mirrored increased expression within the 
lungs and right ventricle, suggesting that altered plasma 
levels may be a surrogate marker of disease activity in 
damaged/remodelled tissues. To our knowledge, the 
only other miRNA previously reported to be concor-
dantly altered in the plasma of human PAH and a 
 Figure 6 – A-C, Assessment of target miRNAs in plasma of patients with 
PAH. A, miRNAs were measured by RT-qPCR in total RNA extracted from 
plasma of 13 healthy control subjects and 14 patients with PAH. miRNA 
levels were normalized to the geomean of two internal reference controls 
(miR-142-3p and -320a) and then expressed relative to the control group. 
# P  , .1, * P  , .05 vs control group. Data are represented as mean   SEM. 
B, PCA of plasma miRNA changes in patients with PAH (  ),  Hx mice 
(  ),  SuHx rats ( L ), and MCT rats (  ). A total of 50.9% of the infor-
mation content associated with the seven-dimensional plasma miRNA 
space is captured in the two-dimensional PCA plot. Ellipses denote 1 SD, 
and line vectors connect to the centroid. C, Receiver operating character-
istic curves of miR-424 and miR-17 plasma levels showing the trade-off  
between sensitivity and specifi city in distinguishing patients with PAH 
from healthy control subjects. PAH  5 pulmonary arterial hypertension. 
See  Figure 1-5 legends for expansion of other abbreviations. 
confi rming the expected inverse regulation between 
miR-322/503 and  Fgf2 in the MCT model, there was 
also evidence of discordance in other models and for 
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 TABLE 1  ]  Summary of Changes in miRNA Levels Associated With Human and Experimental PH 
miRNA 
Human 
(n  5 13-14)
Monocrotaline 
Rats (n  5 10-11)
SU5416  1 Hypoxia 
Rats (n  5 9-13)
Hypoxia Mice 
(n  5 10-11)
Plasma Plasma Lung RV Plasma Lung RV Plasma Lung RV
miR-17  2 1.4 ns ns ns ns ns ns 1.4 ns ns
miR-21 ns 1.3 a 3.2 ns ns ns 2.0 ns 1.6 ns
miR-130b ns 1.3 a  2 1.7 ns ns ns ns ns ns ns
miR-145  2 1.3 a ns  2 2.0  2 1.3 ns 1.2 a ns ns 1.4 ns
miR-204 ns  2 1.5 a  2 1.9 ns ns ns  2 2.0 1.4 a ns ns
miR-424 (322) 1.5  2 1.3  2 3.7 ns ns ns ns 1.3 1.4 1.4
miR-503 ns  2 1.8  2 5.6 ns ns ns ns ns 1.4 1.4
 Fold increase or decrease (vs control group). n denotes sample size/group.  P  , .05 unless otherwise noted. miRNA  5 microRNA; ns  5 not signiﬁ cant; 
PH  5 pulmonary hypertension; RV  5 right ventricle . 
 a P  , .1 (trend). 
rodent model of PH is miR-26a, which was decreased in 
the plasma, lung, and right ventricle of MCT rats, 16 and 
in the plasma 16 and cellular buff y coat 19 of patients with 
PAH. However, unlike miR-424, it remains to be estab-
lished whether miR-26a is causally involved in the devel-
opment of PH in the MCT model, which is currently an 
area of investigation in our laboratory. 
 PAH is a rare disease with prevalence estimated at only 
15 to 26 cases/million, 20,21 making large cohort studies 
inherently challenging. Although the sample size of this 
human patient cohort is limited, it nonetheless can pro-
vide some relevant insight into the relative performance 
of these miRs as potential biomarkers of PH. Of the 
seven miRNAs investigated in this study, only miR-424 
and miR-17 exhibited signifi cant diff erences in plasma 
levels between patients with PAH and healthy control 
subjects. Th e plasma levels of both miRNAs showed 
signifi cant areas under ROC curves, indicative of a good 
balance between sensitivity and specifi city in discrimi-
nating patients with PAH from healthy subjects. 
 Th is study has some limitations, including the small 
sample size and heterogeneity of subjects in the PAH 
cohort. Th e diagnostic usefulness of possible miRNA-
based biomarkers will clearly need to be validated in 
larger prospective cohort studies. It is also uncertain 
what eff ect patients with diff erent forms of PAH and 
therapy may have on comparisons with the more 
well-defi ned experimental forms of PH induced in the 
animal models. Finally, it is important to note that 
cell-specifi c changes in miRNA (or mRNA) expres-
sion, which may underlie disease activity, could be 
obscured by the complex cellular background in tissue 
measurements. 
 Conclusions 
 Despite their previously established roles in the patho-
biology of experimental PH, the majority of miRNAs 
investigated in this study showed limited potential as 
circulating biomarkers of this disease. In addition, three 
separate experimental models of PH showed marked 
disparities in their pattern of miRNA expression 
changes in tissue and plasma. Th ese diff erences have 
important implications for how preclinical models are 
leveraged to gain insight into the molecular mechanisms 
of human PH. 
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